AlphAIAlphAI — Financial news for AI agents
prnewswire.comSEP 221 min read$PKBK

PARKE BANCORP, INC. ANNOUNCES CASH DIVIDEND

Parke Bancorp (NASDAQ: PKBK) declared a $0.20 per share cash dividend, payable October 16, 2026, to shareholders of record by October 2. The board plans quarterly dividends, contingent on financial conditions and regulatory factors. Parke Bancorp operates as a full-service commercial bank in New Jersey and Pennsylvania, with FDIC-insured deposits.

Original reporting
prnewswire.com
Published Sep 22, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$PKBK
Neutral
medium confidence
Mentioned
$PKBK
Relevance
5/10
AlphAI data visualization · based on prnewswire.com
Decision brief

The 30-second read

$PKBKNeutralLow
01

Why it matters

Provides a new corporate action for a small‑cap bank, offering modest income potential.

02

Market read

Dividend announcement may attract income investors but limited overall market effect.

03

What to watch

Future dividend payments depend on regulatory approval and financial condition.

Relevance 5/10Novelty 6/10Timing: announced Sep 22, 2026

Background

Press release from Parke Bancorp detailing its first cash dividend declaration.

Company-level read

Ticker impact

$PKBKNeutralMedium confidence
Context

Parke Bancorp announced a $0.20 per share cash dividend payable Oct 16, 2026.

Expected impact

Potential slight upside as dividend‑seeking buyers accumulate shares.

Evidence & confidence

The dividend is modest and the company is small‑cap; impact is limited but could provide a short‑term price bump.

Market effects

Sector

May signal stability for regional community banks, but limited broader sector impact.

Regional

Minor effect on New Jersey banking sector sentiment.

Global

None

Counterpoint

What could challenge this read

Dividend may be unsustainable if earnings weaken; investors could be wary.

Key entities

  • Company
    Parke Bancorp, Inc.

    NASDAQ‑listed community bank announcing dividend.

Read at source← All news

Related articles

OCT 21
$PKBKHigh

PARKE BANCORP, INC. ANNOUNCES THIRD QUARTER 2026 EARNINGS

PARKE BANCORP, INC. (PKBK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Parke Bancorp, Inc. 601 Delsea Drive, Washington Township, NJ 08080 Contact: Vito S. Pantilione, President and CEO Jonathan D. Hill, Senior Vice President and CFO (856) 256-2500 PARKE BANCORP, INC. ANNOUNCES THIRD QUARTER 2026 EARNINGS Highlights: Net Income: $12.2 m

SEC EDGAR 8-K2 min
JUL 22
$PKBKMed

PARKE BANCORP, INC. ANNOUNCES SECOND QUARTER 2026 EARNINGS

PARKE BANCORP, INC. (PKBK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_970396.htm EXHIBIT 99.1 ex_970396.htm Exhibit 99.1 Parke Bancorp, Inc. 601 Delsea Drive, Washington Township, NJ 08080 Contact: Vito S. Pantilione, President and CEO Jonathan D. Hill, Senior Vice President and CFO (856) 256-2500 PARKE BANCORP, INC. ANNOUNCES SECOND Q

SEC EDGAR 8-K4 min
OCT 21
$ABTHigh

Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027

Abbott Laboratories (ABT) plans to spin off its Nutrition division, generating $8.5B in annual revenue, into a separate publicly traded company by the end of 2027. The move, subject to approvals, will allow Abbott to focus on medical devices, diagnostics, and pharmaceuticals, with the new company led by Daniel Salvadori. Existing shareholders will receive shares in both entities, and the transaction is not expected to affect Abbott's 2026 or 2027 financial guidance.

finance.yahoo.com2 min
OCT 21
$ABTMed

Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits?

Abbott Laboratories (ABT) shares dropped 4% after announcing plans to spin off its Nutrition business, including Similac, by 2027. The unit generates $8.5B annually but has shown minimal growth. The move leaves Abbott with a medical device and diagnostics business, with $42B in annual sales. The company expects to maintain its 2026 guidance and current dividend payouts. Daniel Salvadori will lead the new nutrition company.

finance.yahoo.com2 min
OCT 21
$UDRHigh

UDR, Apollo form $2B joint venture

UDR and Apollo are forming a $2B joint venture for 19 apartment properties. Apollo will invest $1.34B for a two-thirds stake, while UDR retains one-third and will manage the portfolio. UDR plans to use proceeds for high-growth assets, debt reduction, and corporate purposes. The transaction implies a 6% cap rate and is expected to close on Oct. 29.

finance.yahoo.com2 min
OCT 21
$ABTHighAI 8/10

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

ABBOTT LABORATORIES (ABT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies • The new Nutrition company will be a gl

SEC EDGAR 8-K3 min